Interplay of Vitamin D, erythropoiesis, and the renin-angiotensin system

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Santoro, Domenico ^a   Caccamo, Daniela ^b   Lucisano, Silvia ^a   Buemi, Michele ^a   Sebekova, Katerina ^c   Teta, Daniel ^d   De Nicola, Luca ^e  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Faculty of Natural Sciences   (Slovakia)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; OXYGENASE; PARICALCITOL; RENIN; VITAMIN D; VITAMIN D DERIVATIVE;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROPOIESIS; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MINERAL METABOLISM; NONHUMAN; NUTRITIONAL STATUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITAMIN D DEFICIENCY; ANIMAL; METABOLISM;

ANIMALS; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84929376516     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/145828     Document Type: Review

References (103)

1. T. H. Jafar, P. C. Stark, C. H. Schmid et al. , "Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis," Annals of Internal Medicine, vol. 139, no. 4, pp. 244-252, 2003.
2. G. F. M. Strippoli, M. Craig, F. P. Schena, and J. C. Craig, "Antihypertensive agents for primary prevention of diabetic nephropathy," Journal of theAmericanSociety ofNephrology, vol. 16, no. 10, pp. 3081-3091, 2005.
3. S. Yusuf, K. K. Teo, J. Pogue et al. , "Telmisartan, ramipril, or both in patients at high risk for vascular events," New England Journal of Medicine, vol. 358, no. 15, pp. 1547-1559, 2008.
4. L. F. Fried, N. Emanuele, J. H. Zhang et al. , "Combined angiotensin inhibition for the treatment of diabetic nephropathy," The New England Journal of Medicine, vol. 369, no. 20, pp. 1892-1903, 2013.
5. A. H. J. Danser, "The increase in renin during renin inhibition: Does it result in harmful effects by the (pro)renin receptor?" Hypertension Research, vol. 33, no. 1, pp. 4-10, 2010.
6. Y. C. Li, "Renoprotective effects of vitamin D analogs," Kidney International, vol. 78, no. 2, pp. 134-139, 2010.
7. Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and C. L. Yan, "Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15896-15901, 2008.
8. O. Lenz, S. J. Elliot, and W. G. Stetler-Stevenson, "Matrixmetalloproteinases in renal development and disease," Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 574-581, 2000.
9. D. Santoro,D. Caccamo, G. Gagliostro et al. , "VitaminDmetabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients," Journal of Nephrology, vol. 26, no. 4, pp. 636-644, 2013.
10. W. Jelkmann, "Molecular biology of erythropoietin," Internal Medicine, vol. 43, no. 8, pp. 649-659, 2004.
11. Y. C. Li, "VitaminDregulation of the renin-angiotensin system," Journal of Cellular Biochemistry, vol. 88,no. 2, pp. 327-331, 2003.
12. N. M. Patel, O. M. Gutiérrez, D. L. Andress, D. W. Coyne, A. Levin, and M. Wolf, "Vitamin D deficiency and anemia in early chronic kidney disease," Kidney International, vol. 77, no. 8, pp. 715-720, 2010.
13. R. Agarwal, "Are vitamin D receptor agonists like angiotensinconverting enzyme inhibitors without side effects?" Kidney International, vol. 77, no. 11, pp. 943-945, 2010.
14. S. Lucisano, E. di Mauro, G. Montalto, V. Cernaro,M. Buemi, and D. Santoro, "Vitamin D and anemia," Journal of Renal Nutrition, vol. 24, no. 1, pp. 61-62, 2014.
15. S. Albitar,R. Genin, M. Fen-Chong, M.-O. Serveaux,D. Schohn, and C. Chuet, "High-dose alfacalcidol improves anaemia in patients on haemodialysis," Nephrology Dialysis Transplantation, vol. 12, no. 3, pp. 514-518, 1997.
16. G. Saab,D. O. Young, Y. Gincherman,K. Giles,K. Norwood, and D. W. Coyne, "Prevalence of vitaminDdeficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients," Nephron-Clinical Practice, vol. 105, no. 3, pp. c132-c138, 2007.
17. P. T. Lac,K. Choi, I.-A. Liu, S. Meguerditchian, S. A. Rasgon, and J. J. Sim, "The effects of changing vitamin D levels on anemia in chronic kidney disease patients: A retrospective cohort review," Clinical Nephrology, vol. 74, no. 1, pp. 25-32, 2010.
18. J. J. Sim, P. T. Lac, I. L. A. Liu et al. , "Vitamin D deficiency and anemia: A cross-sectional study," Annals of Hematology, vol. 89, no. 5, pp. 447-452, 2010.
19. A. Zittermann, A. Jungvogel, S. Prokop et al. , "Vitamin D deficiency is an independent predictor of anemia in end-stage heart failure," Clinical Research in Cardiology, vol. 100, no. 9, pp. 781-788, 2011.
20. H. Chutia, A. A. Ruram, H. Bhattacharyya, P. Boruah, and C. Nath, "Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease," Journal of Laboratory Physicians, vol. 5, no. 1, pp. 51-54, 2013.
21. M. Gallieni,C. Corsi, and D. Brancaccio, "Hyperparathyroidism and anemia in renal failure," The American Journal of Nephrology, vol. 20, no. 2, pp. 89-96, 2000.
22. S.-G. Wu, F.-R. Jeng, S.-Y. Wei et al. , "Red blood cell osmotic fragility in chronically hemodialyzed patients," Nephron, vol. 78, no. 1, pp. 28-32, 1998.
23. M. S. Joy, P. C. Karagiannis, and F. W. Peyerl, "Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment," Journal of Managed Care Pharmacy, vol. 13, no. 5, pp. 397-411, 2007.
24. A. Icardi, E. Paoletti, L. de Nicola, S. Mazzaferro, R. Russo, and M. Cozzolino, "Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation," Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1672-1679, 2013.
25. I. Blazsek, C. Farabos, P. Quittet et al. , "Bone marrow stromal cell defects and 1 alpha, 25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias," Cancer Detection and Prevention, vol. 20, no. 1, pp. 31-42, 1996.
26. S. M. Zughaier, J. A. Alvarez, J. H. Sloan, R. J. Konrad, and V. Tangpricha, "The role of vitamin D in regulating the ironhepcidin-ferroportin axis inmonocytes," Journal of Clinical and Translational Endocrinology, vol. 1, no. 1, pp. e19-e25, 2014.
27. H. Reichel, H. P. Koeffler, and A. W. Normal, "The role of the vitamin D endocrine system in health and disease," The New England Journal of Medicine, vol. 320, no. 15, pp. 980-991, 1989.
28. A. W. Norman, "Minireview: Vitamin D receptor: New assignments for an already busy receptor," Endocrinology, vol. 147, no. 12, pp. 5542-5548, 2006.
29. F. Aucella, R. P. Scalzulli, G. Gatta, M. Vigilante, A. M. Carella, and C. Stallone, "Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo," Nephron. Clinical Practice, vol. 95, no. 4, pp. c121-c127, 2003.
30. D. Santoro, L. Gitto, A. Ferraro, E. Satta, V. Savica, and G. Bellinghieri, "Vitamin D status and mortality risk in patients with chronic kidney disease," Renal Failure, vol. 33,no. 2, Article ID 553303, pp. 184-191, 2011.
31. P. A. Marsden, D. M. Dorfman, T. Collins, B. M. Brenner, S. H. Orkin, and B. J. Ballermann, "Regulated expression of endothelin 1 in glomerular capillary endothelial cells," The American Journal of Physiology-Renal Fluid and Electrolyte Physiology, vol. 261, no. 1, pp. F117-F125, 1991.
32. E. D. Burgess, R. G. Hawkins, and M. Watanabe, "Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension,"The American Journal of Hypertension, vol. 3, no. 12, pp. 903-905, 1990.
33. L. M. Resnick, F. B. Muller, and J. H. Laragh, "Calciumregulating hormones in essential hypertension: Relation to plasma renin activity and sodium metabolism," Annals of Internal Medicine, vol. 105, no. 5, pp. 649-654, 1986.
34. A. Tomaschitz, S. Pilz, E. Ritz et al. , "Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study," Clinica Chimica Acta, vol. 411, no. 17-18, pp. 1354-1360, 2010.
35. J. P. Forman, J. S. Williams, and N. D. L. Fisher, "Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans," Hypertension, vol. 55, no. 5, pp. 1283-1288, 2010.
36. C. W. Park, Y. S. Oh, Y. S. Shin et al. , "Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism," The American Journal of Kidney Diseases, vol. 33, no. 1, pp. 73-81, 1999.
37. Y. C. Li, J. Kong, M. Wei, Z.-F. Chen, S. Q. Liu, and L.-P. Cao, "1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system," Journal of Clinical Investigation, vol. 110, no. 2, pp. 229-238, 2002.
38. J. Kong, G. Qiao, Z. Zhang, S. Q. Liu, and Y. C. Li, "Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium," Kidney International, vol. 74,no. 12, pp. 1577-1581, 2008.
39. W. Yuan, W. Pan, J. Kong et al. , "1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter," Journal of Biological Chemistry, vol. 282, no. 41, pp. 29821-29830, 2007.
40. M. Freundlich, Y. Quiroz, Z. Zhang et al. , "Suppression of reninangiotensin gene expression in the kidney by paricalcitol," Kidney International, vol. 74, no. 11, pp. 1394-1402, 2008.
41. R. M. Fryer, P. A. Rakestraw, M. Nakane et al. , "Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice," Nephron-Physiology, vol. 106, no. 4,pp. p76-p81, 2007.
42. S. S. Fischer, D. S. Kempe, C. B. Leibrock et al. , "Hyperaldosteronism in klotho-deficient mice," The American Journal of Physiology-Renal Physiology, vol. 299, no. 5, pp. F1171-F1177, 2010.
43. D. W. Good, T. George, and B. A. Watts III, "Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway," The American Journal of Physiology-Cell Physiology, vol. 285, no. 5, pp. C1122-C1130, 2003.
44. W. Xiang, J. Kong, S. Chen et al. , "Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems," The American Journal of Physiology-Endocrinology and Metabolism, vol. 288, no. 1, pp. E125-E132, 2005.
45. R. Thadhani, E. Appelbaum, Y. Pritchett et al. , "Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial," Journal of the American Medical Association, vol. 307, no. 7, pp. 674-684, 2012.
46. A. Y.-M. Wang, F. Fang, J. Chan et al. , "Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial," Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 175-186, 2014.
47. H. Tamez, C. Zoccali,D. Packhamet al. , "VitaminDreduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease," American Heart Journal, vol. 164, no. 6, pp. 902-909, 2012.
48. V. Jha, G. Garcia-Garcia, K. Iseki et al. , "Chronic kidney disease: Global dimension and perspectives," The Lancet, vol. 382, no. 9888, pp. 260-272, 2013.
49. B. K. Mahmoodi, K. Matsushita,M. Woodward et al. , "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis," The Lancet, vol. 380, no. 9854, pp. 1649-1661, 2012.
50. C. S. Fox, K. Matsushita, M. Woodward et al. , "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A metaanalysis," The Lancet, vol. 380, pp. 1662-1673, 2012.
51. T. C. Turin, M. James, P. Ravani et al. , "Proteinuria and rate of change in kidney function in a community-based population," Journal of theAmerican Society of Nephrology, vol. 24, no. 10, pp. 1661-1667, 2013.
52. L. de Nicola, P. Chiodini, C. Zoccali et al. , "Prognosis of CKD patients receiving outpatient nephrology care in Italy," Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2421-2428, 2011.
53. L. de Nicola, R. Minutolo, P. Chiodini et al. , "The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care," Kidney International, vol. 82, no. 4, pp. 482-488, 2012.
54. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease," Kidney International Supplements, vol. 3, no. 1, pp. 1-150, 2013.
55. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al. , "Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy," Circulation, vol. 110, no. 8, pp. 921-927, 2004.
56. W. B. A. Eijkelkamp, Z. Zhang, G. Remuzzi et al. , "Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial," Journal of the American Society of Nephrology, vol. 18,no. 5, pp. 1540-1546, 2007.
57. R. E. Schmieder, J. F. E. Mann, H. Schumacher et al. , "Changes in albuminuria predictmortality and morbidity in patients with vascular disease," Journal of theAmerican Society of Nephrology, vol. 22, no. 7, pp. 1353-1364, 2011.
58. A. S. Levey, D. Cattran, A. Friedman et al. , "Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration," American Journal of Kidney Diseases, vol. 54, no. 2, pp. 205-226, 2009.
59. G. Wolf and E. Ritz, "Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications," Kidney International, vol. 67, no. 3, pp. 799-812, 2005.
60. F. Catapano, P. Chiodini, L. de Nicola et al. , "Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression," The American Journal of Kidney Diseases, vol. 52, no. 3, pp. 475-485, 2008.
61. M.-D. Sanchez-Niño, M. Bozic, E. Córdoba-Lanús et al. , "Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy," The American Journal of Physiology-Renal Physiology, vol. 302, no. 6, pp. F647-F657, 2012.
62. S. M. Sprague, F. Llach, M. Amdahl, C. Taccetta, and D. Batlle, "Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism," Kidney International, vol. 63, no. 4, pp. 1483-1490, 2003.
63. M. J. Kim, A. H. Frankel, M. Donaldson et al. , "Oral cholecalciferol decreases albuminuria and urinary TGF-1 in patientswith type 2 diabetic nephropathy on established renin-angiotensinaldosterone systeminhibition," Kidney International, vol. 80,no. 8, pp. 851-860, 2011.
64. L.-J. Liu, J.-C. Lv, S.-F. Shi, Y.-Q. Chen, H. Zhang, and H.-Y. Wang, "Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial," American Journal of Kidney Diseases, vol. 59, no. 1, pp. 67-74, 2012.
65. R. Agarwal, M. Acharya, J. Tian et al. , "Antiproteinuric effect of oral paricalcitol in chronic kidney disease," Kidney International, vol. 68, no. 6, pp. 2823-2828, 2005.
66. P. Alborzi, N. A. Patel, C. Peterson et al. , "Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial," Hypertension, vol. 52, no. 2, pp. 211-212, 2008.
67. S. Fishbane,H. Chittineni, M. Packman, P. Dutka,N. Ali, and N. Durie, "Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial," The American Journal of Kidney Diseases, vol. 54, no. 4, pp. 647-652, 2009.
68. D. de Zeeuw, R. Agarwal, M. Amdahl et al. , "Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial," The Lancet, vol. 376, no. 9752, pp. 1543-1551, 2010.
69. A. Pisani, M. Sabbatini, G. Duro, P. Colomba, and E. Riccio, "Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: A prospective observational study," Nephrology Dialysis Transplantation, 2014.
70. J. Cheng,W. Zhang, X. Zhang, X. Li, and J. Chen, "Efficacy and safety of paricalcitol therapy for chronic kidney disease: Ametaanalysis," Clinical Journal of the American Society of Nephrology, vol. 7, pp. 391-400, 2012.
71. M. H. de Borst, R. Hajhosseiny, H. Tamez, J. Wenger, R. Thadhani, and D. J. A. Goldsmith, "Active vitamin D treatment for reduction of residual proteinuria: A systematic review," Journal of theAmerican Society of Nephrology, vol. 24, no. 11, pp. 1863-1871, 2013.
72. F. L. Nauta, S. J. L. Bakker,W. van Oeveren et al. , "Albuminuria, proteinuria, and novel urine biomarkers as predictors of longterm allograft outcomes in kidney transplant recipients," The American Journal of Kidney Diseases, vol. 57, no. 5, pp. 733-743, 2011.
73. E. Gonzalez, J. Rojas-Rivera, N. Polanco et al. , "Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients," Transplantation, vol. 95, no. 7, pp. e49-e52, 2013.
74. M. Trillini, M. Cortinovis, P. Ruggenenti et al. , "Paricalcitol for secondary hyperparathyroidism in renal transplantation," Journal of the American Society of Nephrology, 2014.
75. M. D. Witham, M. A. Nadir, and A. D. Struthers, "Effect of vitamin D on blood pressure: A systematic review and metaanalysis," Journal of Hypertension, vol. 27, no. 10, pp. 1948-1954, 2009.
76. A. G. Pittas, M. Chung, T. Trikalinos et al. , "Systematic review: Vitamin D and cardiometabolic outcomes," Annals of Internal Medicine, vol. 152, no. 5, pp. 307-314, 2010.
77. H. Tamez and R. I. Thadhani, "Vitamin D and hypertension: An update and review," Current Opinion in Nephrology and Hypertension, vol. 21, no. 5, pp. 492-499, 2012.
78. T. Şeker, M. Gür, G. Yüksel Kalkan et al. , "Serum 25-hydroxyvitamin D level and extent and complexity of coronary artery disease," Journal of Clinical Laboratory Analysis, vol. 28, no. 1, pp. 52-58, 2014.
79. R. Scragg, M. Sowers, and C. Bell, "Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey," American Journal ofHypertension, vol. 20, no. 7, pp. 713-719, 2007.
80. J. P. Forman, E. Giovannucci, M. D. Holmes et al. , "Plasma 25-hydroxyvitamin D levels and risk of incident hypertension," Hypertension, vol. 49, no. 5, pp. 1063-1069, 2007.
81. Y. C. Li, G. Qiao, M. Uskokovic, W. Xiang, W. Zheng, and J. Kong, "Vitamin D: A negative endocrine regulator of the renin-angiotensin systemand blood pressure," Journal of Steroid Biochemistry and Molecular Biology, vol. 89-90, no. 1-5, pp. 387-392, 2004.
82. S. E. Judd, S. N. Raiser, M. Kumari, and V. Tangpricha, "1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A Pilot Seasibility Study," Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 1-2, pp. 445-447, 2010.
83. G. Bernini, D. Carrara, A. Bacca et al. , "Effect of acute and chronic vitamin D administration on systemic renin angiotensin systemin essential hypertensives and controls," Journal of Endocrinological Investigation, vol. 36, no. 4, pp. 216-220, 2013.
84. D. Carrara, M. Bernini, A. Bacca et al. , "Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D," Journal of Renin-Angiotensin-Aldosterone System, vol. 15, no. 1, pp. 82-87, 2014.
85. A. Abdi-Ali,D. D. M. Nicholl, B. R. Hemmelgarn, J. M. MacRae, D. Y. Sola, and S. B. Ahmed, "25-Hydroxyvitamin D status, arterial stiffness and the renin-angiotensin system in healthy humans," Clinical and Experimental Hypertension, vol. 36, no. 6, pp. 386-391, 2014.
86. M. Pfeifer, B. Begerow, H. W. Minne, D. Nachtigall, and C. Hansen, "Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women," Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1633-1637, 2001.
87. J. A. Sugden, J. I. Davies,M. D. Witham, A. D. Morris, and A. D. Struthers, "VitaminDimproves endothelial function in patients withType2diabetesmellitus and lowvitaminDlevels," Diabetic Medicine, vol. 25, no. 3, pp. 320-325, 2008.
88. O. Tarcin, D. G. Yavuz, B. Ozben et al. , "Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects," Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 10, pp. 4023-4030, 2009.
89. Y. Dong, I. S. Stallmann-Jorgensen, N. K. Pollock et al. , "A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-Hydroxyvitamin D, adiposity, and arterial stiffness," Journal of Clinical Endocrinology and Metabolism, vol. 95,no. 10,pp. 4584-4591, 2010.
90. M. B. Elamin, N. O. Abu Elnour, K. B. Elamin et al. , "Vitamin D and cardiovascular outcomes: A systematic review and metaanalysis," Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 1931-1942, 2011.
91. P. Arora, Y. Song, J. Dusek et al. , "Vitamin D therapy in individuals with prehypertension or hypertension: The DAYLIGHT trial," Circulation, vol. 131, no. 3, pp. 254-262, 2015.
92. M. D. Witham, S. Ireland, J. Graeme Houston et al. , "Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: Randomized, controlled trial," Hypertension, vol. 63, no. 4, pp. 706-712, 2014.
93. R. Scragg, S. Slow, A. W. Stewart et al. , "Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: A randomized controlled trial," Hypertension, vol. 64, no. 4, pp. 725-730, 2014.
94. E. Schulz, S. Steven, and T. Münzel, "Is at least one vitamin helping our vasculature? Evidence for an important role of the endothelial vitamin d receptor in regulating endothelial function and blood pressure," Hypertension, vol. 64, no. 6, pp. 1187-1188, 2014.
95. A. Testa, F. Mallamaci, F. A. Benedetto et al. , "Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progressionin end-stage renal disease (ESRD) patients," Journal of Bone and Mineral Research, vol. 25, no. 2, pp. 313-319, 2010.
96. A. M. El-Shehaby,M. M. El-Khatib, S. Marzouk, and A. A. Battah, "Relationship of BsmI polymorphism of vitaminDreceptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients," Scandinavian Journal of Clinical and Laboratory Investigation, vol. 73, no. 1, pp. 75-81, 2013.
97. D. Santoro, G. Gagliostro, A. Alibrandi et al. , "Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease," Nutrients, vol. 6, no. 3,pp. 1029-1037, 2014.
98. Y. Solak, A. Covic, and M. Kanbay, "What do we know and do not know about vitamin D? A causal association between vitamin D receptor genetic polymorphism and hypertension," The Journal of Clinical Hypertension, vol. 16, no. 9, pp. 627-628, 2014.
99. C. M. Kammerer, A. A. Dualan, P. B. Samollow et al. , "Bone mineral density, carotid artery intimal medial thickness, and the vitamin D receptor BsmI polymorphism in Mexican American women," Calcified Tissue International, vol. 75, no. 4, pp. 292-298, 2004.
100. E. Kulah, A. Dursun, S. Acikgoz et al. , "The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene Fok-I polymorphism in essential hypertension," Kidney and Blood Pressure Research, vol. 29, no. 6, pp. 344-350, 2007.
101. N. Swapna, U. Mohana Vamsi, G. Usha, and T. Padma, "Risk conferred by Fokl polymorphism of vitamin D receptor (VDR) gene for essential hypertension," Indian Journal of Human Genetics, vol. 17, no. 3, pp. 201-206, 2011.
102. L. Wang, J. Ma, J. E. Manson, J. E. Buring, J. M. Gaziano, and H. D. Sesso, "A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphisms, and risk of hypertension in men," European Journal of Nutrition, vol. 52, no. 7, pp. 1771-1779, 2013.
103. O. Andrukhova, S. Slavic, U. Zeitz et al. , "Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice,"Molecular Endocrinology, vol. 28,no. 1, pp. 53-64, 2014.